{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T16:42:28Z","timestamp":1780504948725,"version":"3.54.1"},"reference-count":18,"publisher":"Akademiai Kiado Zrt.","issue":"4","license":[{"start":{"date-parts":[[2021,8,5]],"date-time":"2021-08-05T00:00:00Z","timestamp":1628121600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["akjournals.com"],"crossmark-restriction":true},"short-container-title":["IMAS"],"published-print":{"date-parts":[[2021,8,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Pulmonary Arterial Hypertension (PAH) carries a poor prognosis in both adult and pediatric patients. It is a life-threatening condition in newborns. Current recommendations advocate the use of targeted monotherapy as a first-line approach for the treatment of Persistent Pulmonary Hypertension of the Newborn (PPHN). In case of an inadequate clinical response to treatment, an addition of a second or third agent is considered. PAH is usually managed with a phosphodiesterase 5 inhibitor or an endothelin receptor blocker. There are limited pediatric studies that address questions like which class of therapy should be initiated first or if a combination should be initiated together. With this background, the present study was initiated to compare the efficacy, safety, and tolerability of bosentan as an adjuvant to sildenafil and sildenafil alone in PPHN.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 40 patients were enrolled in the study. Out of them, 26 were males (65%) and 14 were females (35%). PPHN was most commonly seen in the 29 (72.5%) of participants with a history of first order birth. Mean duration of symptoms was 14.05 \u00b1 2.06 days. The participants were randomized to two groups. Group A consisted of total 25 participants that received both bosentan and sildenafil and group B had 15 participants that received sildenafil alone. Both groups were comparable in terms of birth weight and present weight, consanguinity, and mode of delivery. Efficacy was determined by the reduction in mean baseline Pulmonary Artery Systolic Pressure (PASP). PASP in group A was 75.56 \u00b1 10.62\u2009mm Hg and in group B was 64.86 \u00b1 12.25\u2009mm Hg which was not statistically significant (<jats:italic>P<\/jats:italic> &gt; 0.05). PASP on the third and seventh day in group A were 43.72 \u00b1 8.63 and 24.47 \u00b1 3.52\u2009mm Hg compared to 42.28 \u00b1 9.43 and 27.276 \u00b1 8.38 respectively in group B which was statistically significant (<jats:italic>P<\/jats:italic> &lt; 0.05).There were two deaths each in both groups. Two participants in Group A developed liver function abnormalities. None of the participants in Group B had adverse effects.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Most common clinical manifestations were nonspecific. Cardiovocal syndrome was common in PPHN. We conclude that oral sildenafil treatment is a safe, simple and effective treatment for persistent pulmonary hypertension in newborn. Combination of bosentan with sildenafil is more effective and safe in reducing pulmonary artery (PA) pressures in high-risk patients with PPHN.<\/jats:p><\/jats:sec>","DOI":"10.1556\/1646.2020.00004","type":"journal-article","created":{"date-parts":[[2021,7,19]],"date-time":"2021-07-19T05:09:00Z","timestamp":1626671340000},"page":"216-220","update-policy":"https:\/\/doi.org\/10.1556\/policypage.crossmark.crossref.1","source":"Crossref","is-referenced-by-count":2,"title":["Efficacy, safety and tolerability of bosentan as an adjuvant to sildenafil and sildenafil alone in persistant pulmonary hypertension of newborn (PPHN)"],"prefix":"10.1556","volume":"11","author":[{"given":"J.R.","family":"Vijay Kumar","sequence":"first","affiliation":[{"name":"Sri Jayadeva Institute of Cardiovascular Sciences and Research, Bangalore, Karnataka, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3582-8639","authenticated-orcid":true,"given":"H.S.","family":"Natraj Setty","sequence":"additional","affiliation":[{"name":"Sri Jayadeva Institute of Cardiovascular Sciences and Research, Bangalore, Karnataka, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Jayaranganath","sequence":"additional","affiliation":[{"name":"Sri Jayadeva Institute of Cardiovascular Sciences and Research, Bangalore, Karnataka, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.N.","family":"Manjunath","sequence":"additional","affiliation":[{"name":"Sri Jayadeva Institute of Cardiovascular Sciences and Research, Bangalore, Karnataka, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"425","reference":[{"key":"ref31","first-page":"1683","article-title":"Successful treatment of persistent pulmonary hypertension of the newborn with bosentan","volume":"98","author":"Nakwan","year":"2009","journal-title":"ActaPaediatr"},{"key":"ref101","first-page":"405","article-title":"Persistent pulmonary hypertension of the newborn: role of nitric oxide and endothelin in pathophysiology and treatment","volume":"22","author":"Steinhorn","year":"1995","journal-title":"ClinPerinatol"},{"key":"ref111","first-page":"591","article-title":"New approaches for persistent pulmonary hypertension of newborn","volume":"31","author":"Konduri","year":"2004","journal-title":"ClinPerinatol"},{"key":"ref61","first-page":"372","article-title":"Pharmacokinetics, safety, and efficacity of bosentan in pediatric patients with pulmonary arterialhypertension","volume":"73","author":"Barst","year":"2003","journal-title":"ClinPharmacolTher"},{"key":"ref81","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/S0022-3476(85)80534-5","article-title":"Congenital diaphragmatic hernia: arterial structural changes and persistent pulmonary hypertension after surgical repair","volume":"107","author":"Geggel","year":"1985","journal-title":"J Pediatr"},{"key":"ref171","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/S0022-3476(85)80534-5","article-title":"Congenital diaphragmatic hernia: arterial structural changes and persistent pulmonary hypertension after surgical repair","volume":"107","author":"Geggel","year":"1985","journal-title":"J Pediatr"},{"key":"ref151","first-page":"372","article-title":"Pharmacokinetics, safety, and efficacity of bosentan in pediatric patients with pulmonary arterialhypertension","volume":"73","author":"Barst","year":"2003","journal-title":"ClinPharmacolTher"},{"key":"ref71","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1007\/s00431-007-0531-y","article-title":"Persistent pulmonary hypertension of the newborn with transposition of the great arteries: successful treatment with bosentan","volume":"167","author":"Goissen","year":"2008","journal-title":"Eur J Pediatr"},{"key":"ref11","first-page":"405","article-title":"Persistent pulmonary hypertension of the newborn: role of nitric oxide and endothelin in pathophysiology and treatment","volume":"22","author":"Steinhorn","year":"1995","journal-title":"ClinPerinatol"},{"key":"ref91","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1164\/ajrccm.151.6.7767553","article-title":"Persistent pulmonary hypertension of the newborn: state of the art","volume":"151","author":"Morin","year":"1995","journal-title":"Am J Respircrit Care Med"},{"key":"ref121","first-page":"1683","article-title":"Successful treatment of persistent pulmonary hypertension of the newborn with bosentan","volume":"98","author":"Nakwan","year":"2009","journal-title":"ActaPaediatr"},{"key":"ref01","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1164\/ajrccm.151.6.7767553","article-title":"Persistent pulmonary hypertension of the newborn: state of the art","volume":"151","author":"Morin","year":"1995","journal-title":"Am J Respircrit Care Med"},{"key":"ref21","first-page":"591","article-title":"New approaches for persistent pulmonary hypertension of newborn","volume":"31","author":"Konduri","year":"2004","journal-title":"ClinPerinatol"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1016\/S0735-1097(03)00121-9","article-title":"Effects of the oral endothelin-receptor antagonist bosentan on echocardiographic and Doppler measures in patients with pulmonary arterial hypertension","volume":"41","author":"Galie","year":"2003","journal-title":"J Am Collcardiol"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1056\/NEJMoa012212","article-title":"Bosentan therapy for pulmonary arterial hypertension","volume":"346","author":"Rubin","year":"2002","journal-title":"N Engl J Med"},{"key":"ref141","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1056\/NEJMoa012212","article-title":"Bosentan therapy for pulmonary arterial hypertension","volume":"346","author":"Rubin","year":"2002","journal-title":"N Engl J Med"},{"key":"ref131","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1016\/S0735-1097(03)00121-9","article-title":"Effects of the oral endothelin-receptor antagonist bosentan on echocardiographic and Doppler measures in patients with pulmonary arterial hypertension","volume":"41","author":"Galie","year":"2003","journal-title":"J Am Collcardiol"},{"key":"ref161","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1007\/s00431-007-0531-y","article-title":"Persistent pulmonary hypertension of the newborn with transposition of the great arteries: successful treatment with bosentan","volume":"167","author":"Goissen","year":"2008","journal-title":"Eur J Pediatr"}],"container-title":["Interventional Medicine and Applied Science"],"original-title":[],"link":[{"URL":"https:\/\/akjournals.com\/view\/journals\/1646\/11\/4\/article-p216.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/akjournals.com\/downloadpdf\/journals\/1646\/11\/4\/article-p216.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,19]],"date-time":"2021-10-19T00:40:35Z","timestamp":1634604035000},"score":1,"resource":{"primary":{"URL":"https:\/\/akjournals.com\/view\/journals\/1646\/11\/4\/article-p216.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,5]]},"references-count":18,"journal-issue":{"issue":"4"},"URL":"https:\/\/doi.org\/10.1556\/1646.2020.00004","relation":{},"ISSN":["2061-1617","2061-5094"],"issn-type":[{"value":"2061-1617","type":"print"},{"value":"2061-5094","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,5]]}}}